Breaking News
January 17, 2018 - Raw Meat Not the Safest Choice for Your Dog or for You
January 17, 2018 - High-Dose Aspirin Preferred for Kawasaki’s
January 17, 2018 - Study suggests risk management approach to combat EMS fatigue
January 17, 2018 - A new therapy against obesity
January 17, 2018 - Doctors warn against holding your nose and closing your mouth to contain a sneeze
January 17, 2018 - Measles outbreak alarms public health officials
January 17, 2018 - FDA Slaps Class Warning on Gadolinium Contrast Agents
January 17, 2018 - Distinct human mutations can alter the effect of medicine
January 17, 2018 - ASIT biotech’s new article presents clinical results of gp
January 17, 2018 - Alternative tobacco use by adolescents associated with greater odds of future cigarette smoking
January 17, 2018 - A High-Salt Diet Produces Dementia In Mice
January 17, 2018 - Scientists provide insights into crucial interaction for DNA repair
January 17, 2018 - Sanofi and Regeneron Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
January 17, 2018 - Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
January 17, 2018 - Researchers see gene influencing performance of sleep-deprived people
January 17, 2018 - Fast food triggers the immune system making it hyperactive
January 17, 2018 - Scientists find increased risk of HIV outbreaks in Ukraine due to war-related migration
January 17, 2018 - New universal flu vaccine moves to clinical trial phase and could be a reality soon
January 17, 2018 - Cocaine de-addiction breakthrough shows promise
January 17, 2018 - FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
January 17, 2018 - Robotic Telestenting; BP Cuff Smartwatch; Medicare Bundled Care
January 17, 2018 - New cellular approach found to control progression of chronic kidney disease
January 17, 2018 - Lamprey genes provide clues to repair spinal cord damage, finds study
January 17, 2018 - Tissue-based soft robot could lead to advances in bio-inspired robotics
January 17, 2018 - Mostly the healthy and wealthy Americans use mobile phone apps to track sleep habits
January 17, 2018 - FDA Alert: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter
January 16, 2018 - NeuroBreak: Rough Days for Neuroscience Research; Another Migraine Drug Advances
January 16, 2018 - The ‘greatest pandemic in history’ was 100 years ago – but many of us still get the basic facts wrong
January 16, 2018 - Serena Williams Shares Childbirth Ordeal
January 16, 2018 - The Artificial Brain as Doctor
January 16, 2018 - Type 2 diabetes has hepatic origins
January 16, 2018 - Expert discusses how to identify, support individuals with drug or alcohol addiction in workplace
January 16, 2018 - Starting menstruation early increases risk of cardiovascular disease and stroke in later life
January 16, 2018 - CapsoVision receives CE Mark approval for use of CapsoCam Plus System in pediatric patients
January 16, 2018 - Researchers develop new dynamic statistical model to follow gene expressions over time
January 16, 2018 - Alzheimer’s ‘looks like me, it looks like you’
January 16, 2018 - By the Numbers: Physicians’ Economic Impact
January 16, 2018 - Sound Health | NIH News in Health
January 16, 2018 - Modifying baby formula doesn’t prevent type 1 diabetes in children
January 16, 2018 - Energy drinks dangerous for kids
January 16, 2018 - When you need a breast screening, should you get a 3-D mammogram?
January 16, 2018 - Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - How fatal mitochondrial diseases may strike offspring of families with no history of the conditions
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - ViLim Ball technology helps reduce uncontrollable shaking hands
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
January 16, 2018 - In Wisconsin, hopes rise for production of a lifesaving radioactive isotope
January 16, 2018 - Researchers develop software to better predict risk of leakage around aortic stents
January 16, 2018 - Bile acids could directly burn away lipids in the fat depots
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Severe peer victimization in childhood may contribute to mental health issues in adolescence
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
Combo Treatment Offers New Hope in Tough-to-Treat CLL

Combo Treatment Offers New Hope in Tough-to-Treat CLL

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • The combination treatment of ibrutinib (Imbruvica) with venetoclax (Venclexta) was well tolerated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
  • After 6 months of the combo therapy, 84% had no morphological evidence of CLL in the marrow biopsy, and 76% had less than 1% CLL cells in the marrow.

ATLANTA — The combination treatment of ibrutinib (Imbruvica) with venetoclax (Venclexta) was well tolerated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), researchers reported here.

In preliminary results from the CLARITY trial, 38 of 54 patients treated with the combination (IBR+VEN) responded to the therapy after 6 months, and 15 of those patients achieved a complete response, according to Peter Hillmen, MBChB, PhD, of the University of Leeds in England, and colleagues.

In addition, only two of 41 patients experienced biochemical tumor lysis syndrome (TLS) to date, they said in a presentation at the American Society of Hematology (ASH) meeting.

“Ibrutinib is an oral BTK-inhibitor affecting antigen-induced proliferation and cell adhesion/migration whilst venetoclax is a potent, highly selective, orally bioavailable Bcl-2 inhibitor affecting CLL cell survival,” the authors wrote. “Ibrutinib treatment leads to a rapid nodal response with re-distribution of CLL into the peripheral blood, whereas venetoclax leads to depletion of CLL cells to levels where they cannot be detected in some patients. Ibrutinib leads to reduction of anti-apoptotic molecules such as MCL1, hence theoretically potentiating the effect of venetoclax.”

The CLARITY trial is a feasibility study to investigate the safety and efficacy of the combination treatment in patients with relapsed/refractory CLL.

The trial enrolled 50 CLL patients who required therapy, and who had either relapsed within 3 years of chemoimmunotherapy (h fludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab), or had 17p deletion and had failed at least one line of therapy.

After 8 weeks of ibrutinib monotherapy (420mg/day), venetoclax was added first at a dose of 10mg/day, with weekly escalations to 20mg, 50mg, 100mg, and 200mg. The final dose was 400mg/day. No TLS was seen for the first three patients starting at 10mg/day of venetoclax, so all subsequent patients began venetoclax at 20mg/day.

Hillmen told MedPage Today that the plan is to treat the patients with a complete response for another 6 months, and then take them off medication for CLL to determine if the remission is durable. “

We are just getting to the point now where we will be taking patients off medication,” he said. “We cannot detect residual disease that may be lingering, so we want to extend therapy another 6 months so we can decrease even this undetectable disease several logs lower to the point that the disease may not ever come back.”

There were 37 men and 17 women in the study with a median age of 62. About 92% of the patients were in ECOG performance status of 0 or 1.

The trial’s primary endpoint is minimal residual disease (MRD) eradication, defined as <1 CLL cell in 104 assessed by 8-color flow in the marrow after 12 months of combination therapy. A key secondary endpoints is safety, with laboratory and clinical TLS defined as critical safety events, the authors explained.

All of the patients were given prophylactic uric acid-reducing agents beginning at least 72 hours prior to starting venetoclax, the authors noted. Over the first 3 months of combined therapy, the level of CLL in the peripheral blood was monitored weekly during venetoclax escalation and then every month after that.

The authors reported that the median number of prior therapies was two, including FCR or BR in 94%. Among 45 patients, 20% had 17p deleted, 27% had 11q deleted, and 77% had unmutated VH genes.

Of the two biochemical TLS events reported, one was an increase in creatinine and phosphate, and the other was an isolated phosphate increase, which did not meet the definition of TLS, according to the authors. Dosing of venetoclax was interrupted until the biochemical abnormalities resolved and these patients subsequently escalated to 400mg/day of venetoclax with no further TLS.

As for safety, there were five grade 3 or 4 infections, and 19 episodes of grade 3 or 4 neutropenia. All serious adverse events resolved with appropriate management and all patients remained on therapy following resolution. There were no fatal adverse events.

After 6 months of the combo therapy, 84% (21/25) had no morphological evidence of CLL in the marrow biopsy, and 76% had less than 1% CLL cells in the marrow. Also, 28% achieved an MRD negative remission (<10-4).

“Patients will continue IBR+VEN for the same duration of time as it took them to achieve MRD negativity (i.e. patients who are MRD negative after 6 months IBR+VEN will stop both drugs after 12 months of IBR+VEN). Therefore all patients will continue on IBR+VEN until at least the 14 month assessment (after 12 months of IBR+VEN),” the authors wrote.

“These early results suggest a potent synergy between ibrutinib and venetoclax,” they concluded.

ASH press conference moderator Laurie Sehn, MD, of the British Columbia Cancer Agency in Vancouver, called the results “truly exciting…we are moving towards an era where we can use these targeted therapies to replace some of the toxic agents used to treat hematological disorders.”

“When I trained, CLL was a boring disease to work with because it was a chronic condition, and there were limited treatment options,” she noted. “Now what we have seen with CLL has just been a explosion of an understanding of the disease that has resulted in drugs that have transformed our ability to treat patients. Data like this study are exactly where we want to see the field going. The ability to combine drugs rationally to make them work even better is exciting.”

She called the high response rate “highly impressive…It gives the promise that some of these patients may be cured. This is a first step in moving toward that direction.”

Hillmen disclosed relevant relationships with Gilead, Janssen, GSK, Celgene, AbbVie Company, Novartis, Roche, and Alexion Pharmaceuticals. Co-authors disclosed multiple relevant relationships with industry.

Sehn disclosed relevant relationships with Janssen, Amgen, Seattle Genetics, Abbvie, Celgene, and Roche/Genentech.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-10T17:33:16-0500

Tagged with:

About author

Related Articles